Sarepta Therapeutics Inc (SRPT) Moves Ahead With Seeking Eteplirsen Approval: Hip, Hip, Uh-Oh?

Sarepta’s news on Wednesday didn’t have too many investors cheering. However, my view is that this pullback could be a good buying opportunity for those willing to hold on through the uncertainty. I think that eteplirsen will gain FDA approval — sooner or later. “Hoorays” will be in order eventually for Sarepta shareholders and, more importantly, for those young boys with DMD and their families.

The article Sarepta Moves Ahead With Seeking Eteplirsen Approval: Hip, Hip, Uh-Oh? originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.